New Drugs Get "Luck Of The Draw" In FDA's First Round Of 18-Month Reviews
This article was originally published in The Pink Sheet Daily
Executive Summary
"We're not being surprised by anything we are seeing" in the initial batch of FDAAA-mandated post-market assessments, FDA's Boucher says.
You may also be interested in...
Postmarketing Safety: US FDA ‘Best Practices’ Include Weekly Adverse Event Screening For New Drugs
Agency’s approach to risk-based postmarketing safety surveillance explained in new draft document issued under the 21st Century Cures Act; product characteristics and intended use guide the frequency and extent of adverse event report screening, with newer drugs undergoing weekly reviews for three years after approval.
FDA Seeks To Write MedGuides Outside REMS Process
Agency advice on REMS evolves as FDA gains experience with the program, OSE Director Dal Pan says at DIA.
FDA Seeks To Write MedGuides Outside REMS Process
Agency advice on REMS evolves as FDA gains experience with the program, OSE Director Dal Pan says at DIA.